The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613-Reference-Cited by-同舟云学术

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613

Published:2017-09 Issue:5 Volume:18 Page:583-588
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Remon Jordi,Menis Jessica,Hasan Baktiar,Peric Aleksandra,De Maio Eleonora,Novello Silvia,Reck Martin,Berghmans Thierry,Wasag Bartosz,Besse Benjamin,Dziadziuszko Rafal

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. EGFR mutation incidence in non–small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII);Midha;Am J Cancer Res,2015

2. Routine molecular profiling of patients with advanced non–small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

3. Common EGFR-mutated subgroups (Del19/L858R) in advanced non–small-cell lung cancer: chasing better outcomes with tyrosine-kinase inhibitors;Reguart;Future Oncol,2015

4. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

5. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay;Arcila;Clin Cancer Res,2011

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways;Critical Reviews in Oncology/Hematology;2024-07

2. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer;Cancers;2024-06-12

3. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors;JCO Precision Oncology;2024-02

4. Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer;Clinical Pharmacology & Therapeutics;2023-12-21

5. Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages;Acta Pharmacologica Sinica;2023-12-19